NCT03646994 2023-12-27
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Unknown
Clinical Trials
13 trialsNCT03647111 2023-12-27
Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Unknown
NCT04632758 2023-11-24
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03574402 2022-12-06
TRUMP
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT05204628 2022-01-24
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04292119 2021-03-10
Lorlatinib Combinations in Lung Cancer
Massachusetts General Hospital
Phase 1/2 Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT04009317 2019-10-30
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT03874273 2019-03-14
Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Unknown
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT02499614 2017-10-25
METROS
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT02946359 2016-11-02
A+C in Metastatic Lung Adenocarcinoma Cancer
Chinese PLA General Hospital
Phase 2 Unknown